Zebrafish xenografts as a fast screening platform for bevacizumab cancer therapy

Despite promising preclinical results, average response rates to anti-VEGF therapies, such as bevacizumab, are reduced for most cancers, while incurring in remarkable costs and side effects. Currently, there are no biomarkers available to select patients that can benefit from this therapy. Depending...

詳細記述

保存先:
書誌詳細
出版年:Commun Biol
主要な著者: Rebelo de Almeida, Cátia, Mendes, Raquel Valente, Pezzarossa, Anna, Gago, Joaquim, Carvalho, Carlos, Alves, António, Nunes, Vitor, Brito, Maria José, Cardoso, Maria João, Ribeiro, Joana, Cardoso, Fátima, Ferreira, Miguel Godinho, Fior, Rita
フォーマット: Artigo
言語:Inglês
出版事項: Nature Publishing Group UK 2020
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7286887/
https://ncbi.nlm.nih.gov/pubmed/32523131
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s42003-020-1015-0
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料